Sign In
Buy ADC
$72.03
-0.650 (-0.89%)
At Close: Jun 03, 2026
Company to host conference call today at 4:30 p.m. EDT LAUSANNE, Switzerland, June 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced topline data from its Phase 3 LOTIS-5 confir
Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor â palbociclib
Agree Realty Is Becoming More And More Attractive, But I'm Not Buying Yet
06:29am, Tuesday, 02'nd Jun 2026
ADC remains a hold due to its still-elevated valuation despite robust business fundamentals and portfolio quality. ADC boasts a high share of investment-grade tenants (over 65%) and strong sector dive
Whitehawk Therapeutics Presents RealâWorld Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neur
U.S. REIT At-The-Market Activity Dips In Q1 2026
03:55am, Thursday, 28'th May 2026
Thirty-three US REITs utilized their at-the-market (ATM) offering programs during the recent quarter, raising $4.15 billion in aggregate proceeds. Healthcare REIT Welltower Inc. raised the most capita
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
05:05pm, Thursday, 21'st May 2026
Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload Variations Hangzhou DAC's DXC006 Data at ASCO Reinforce Conviction for CPT113,
Merck's ADC Candidate Meets Goals in Endometrial Cancer Study
12:50pm, Tuesday, 19'th May 2026
MRK's investigational TROP2-directed ADC, sac-TMT, achieves key survival goals in a phase III endometrial cancer study.
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities
03:15am, Tuesday, 19'th May 2026
Montreal, Quebec--(Newsfile Corp. - May 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracell
AstraZeneca and Daiichi Sankyo's ENHERTUÂ (fam-trastuzumab deruxtecan-nxki) has been approved by the US Food and Drug Administration (FDA) for both the neoadj
Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting
04:25am, Friday, 15'th May 2026
Whitehawk Therapeutics pivots to focus on three next-generation antibody-drug conjugates [ADCs] after selling FYARRO and rebranding from Aadi Bioscience. I downgrade WHWK from 'Strong Buy' to 'Hold' d
Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease
09:00pm, Wednesday, 13'th May 2026
Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease PR Newswire
Agree Realty Declares Monthly Common and Preferred Dividends
04:05pm, Tuesday, 12'th May 2026
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash div
Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications Patent reinforces strategic foundation for lead ADC A
InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China
10:25pm, Wednesday, 06'th May 2026
BEIJING, May 06, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today th
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program
08:00am, Wednesday, 06'th May 2026
PARIS--(BUSINESS WIRE)--Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital p
